1. Home
  2. NTZ vs BOLD Comparison

NTZ vs BOLD Comparison

Compare NTZ & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natuzzi S.p.A.

NTZ

Natuzzi S.p.A.

N/A

Current Price

$3.00

Market Cap

34.3M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.57

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTZ
BOLD
Founded
1959
2018
Country
Italy
United States
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
34.3M
36.5M
IPO Year
1998
2024

Fundamental Metrics

Financial Performance
Metric
NTZ
BOLD
Price
$3.00
$1.57
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
2.5K
374.5K
Earning Date
04-13-2023
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.96
52 Week High
$4.46
$1.72

Technical Indicators

Market Signals
Indicator
NTZ
BOLD
Relative Strength Index (RSI) 49.46 65.74
Support Level $2.59 $1.12
Resistance Level $3.17 N/A
Average True Range (ATR) 0.20 0.07
MACD -0.01 -0.00
Stochastic Oscillator 71.98 57.69

Price Performance

Historical Comparison
NTZ
BOLD

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: